Business Wire10.02.20
TransEnterix Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that Shameze Rampertab has been appointed as the company’s executive vice president and chief financial officer (CFO).
“We are delighted to welcome Shameze to our team during this important time in TransEnterix’s journey,” said Anthony Fernando, TransEnterix president and CEO. “His extensive experience at implementing financial strategies and sourcing equity and debt financing options will be invaluable as we continue towards our goals for 2020 and beyond. I am confident Shameze will make an immediate positive impact on the organization and help lead TransEnterix through its next phase of growth.”
Rampertab brings over 20 years of financial leadership experience in the healthcare sector to the company. In addition to significant experience in corporate leadership roles, his background also includes time spent as an investment banker and sell-side equity research analyst. Most recently, Rampertab served as interim CEO (December 2019 to June 2020), CFO (March 2016 to August 2020), and corporate secretary and a director (April 2016 to August 2020) at Zomedica Pharmaceuticals Corp., an animal health company. Before joining Zomedica, he served as CFO and secretary (October 2014 to November 2015) at Profound Medical Corp., a thermal ablation medical device company. Prior to that, he was CFO and vice president of Finance (October 2010 to October 2014) for Intellipharmaceutics International Inc., a NASDAQ and TSX listed specialty pharmaceutical company.
Rampertab received his Chartered Professional Accountant (CPA) and Chartered Accountant (CA) designations from the Chartered Professional Accountants of Canada, and earned his MBA from McMaster University and a bachelor of science degree in molecular genetics and molecular biology from the University of Toronto.
Rampertab added, “I am thrilled to join TransEnterix, a company I have long admired for its innovative robotic solutions to enable digital laparoscopy. I look forward to working with Anthony and the entire team to deliver commercial adoption and drive long-term growth.”
“We are delighted to welcome Shameze to our team during this important time in TransEnterix’s journey,” said Anthony Fernando, TransEnterix president and CEO. “His extensive experience at implementing financial strategies and sourcing equity and debt financing options will be invaluable as we continue towards our goals for 2020 and beyond. I am confident Shameze will make an immediate positive impact on the organization and help lead TransEnterix through its next phase of growth.”
Rampertab brings over 20 years of financial leadership experience in the healthcare sector to the company. In addition to significant experience in corporate leadership roles, his background also includes time spent as an investment banker and sell-side equity research analyst. Most recently, Rampertab served as interim CEO (December 2019 to June 2020), CFO (March 2016 to August 2020), and corporate secretary and a director (April 2016 to August 2020) at Zomedica Pharmaceuticals Corp., an animal health company. Before joining Zomedica, he served as CFO and secretary (October 2014 to November 2015) at Profound Medical Corp., a thermal ablation medical device company. Prior to that, he was CFO and vice president of Finance (October 2010 to October 2014) for Intellipharmaceutics International Inc., a NASDAQ and TSX listed specialty pharmaceutical company.
Rampertab received his Chartered Professional Accountant (CPA) and Chartered Accountant (CA) designations from the Chartered Professional Accountants of Canada, and earned his MBA from McMaster University and a bachelor of science degree in molecular genetics and molecular biology from the University of Toronto.
Rampertab added, “I am thrilled to join TransEnterix, a company I have long admired for its innovative robotic solutions to enable digital laparoscopy. I look forward to working with Anthony and the entire team to deliver commercial adoption and drive long-term growth.”
